Alder biopharmaceuticals inc (ALDR)
CashFlow / Yearly
Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Operating activities
Net loss

-296,429

-288,879

-156,254

-85,470

8,908

-20,613

-17,806

Adjustments to reconcile net loss to net cash used in operating activities
Non-cash gain on license of clazakizumab in exchange for investment in unconsolidated entity

-

-

1,050

-

-

-

-

Equity in net loss of unconsolidated entity

-222

-643

-185

-

-

-

-

Depreciation and amortization

2,567

3,001

1,674

751

701

935

1,042

Loss on retirement of property and equipment

-

-

-

-

-2

-43

-

Stock-based compensation

25,420

22,498

13,957

6,139

1,250

575

489

Accretion of discount on convertible notes

10,596

-

-

-

-

-

-

Non-cash change in fair value of derivative liability

-1,658

-

-

-

-

-

-

Other non-cash charges, net

3,142

167

-407

-17

-

-

-

Interest expense related to convertible promissory note payable

-

-

-

-

-

-

88

Changes in operating assets and liabilities
Accounts receivable

-

-

-

-113

-203

188

-1,181

Prepaid expenses and other assets

-3,574

-37,366

31,374

9,744

5,196

-1,053

-215

Inventory

-

-936

936

-

-

-

-

Accounts payable

1,273

-2,395

5,488

2,816

-312

303

-223

Accrued liabilities

3,414

366

7,843

4,273

835

142

650

Deferred rent

-3

14

373

-128

276

-129

-149

Deferred revenue

-

-

-

-

-54,324

-18,253

-15,389

Net cash used in operating activities

-250,850

-226,617

-159,687

-81,233

-47,657

-36,132

-29,902

Investing activities
Purchases of investments

522,795

305,540

165,871

185,629

11,045

-

8,025

Proceeds from maturities of investments

321,629

341,819

104,765

19,335

1,960

5,620

7,549

Proceeds from sales of investments

83,184

151

-

250

-

-

-

Purchases of property and equipment

3,136

2,050

6,619

1,223

649

193

1,031

Proceeds from sale of property and equipment

-

-

5

-

-

-

-

Decrease in restricted cash

-

-

-

-

-

119

-

Net cash provided by (used in) investing activities

-121,118

34,380

-67,720

-167,267

-9,734

5,546

-1,507

Financing activities
Deferred offering costs

-

-

-

-36

36

-

-

Proceeds from issuance of 2025 convertible senior notes, net of offering costs

277,656

-

-

-

-

-

-

Proceeds from issuance of convertible preferred stock, net of offering costs

97,710

-

-

-

-

-

37,857

Proceeds from issuance of common stock, net of offering costs

-

161,482

134,871

406,634

80,259

-

-

Proceeds from exercise of stock options and employee stock purchase plan

2,571

1,435

2,239

1,536

759

48

48

Net cash provided by financing activities

377,937

162,917

137,110

408,206

80,982

48

37,905

Effect of exchange rate changes on cash, cash equivalents and restricted cash

-

-

21

-9

-23

12

-3

Net increase in cash, cash equivalents and restricted cash

5,969

-29,320

-90,276

159,697

23,568

-30,526

6,493

Supplemental disclosures:
Cash paid for interest

3,594

-

-

-

-

-

-

Purchases of property and equipment included in accounts payable and accrued liabilities

209

8

503

347

-

-

-

Dividends on convertible preferred stock paid in kind

6,045

-

-

-

-

-

-

Conversion of promissory note payable and accrued interest into convertible preferred stock

-

-

-

-

-

-

5,879

Conversion of convertible preferred stock into common stock

-

-

-

-

111,374

-

-